Medijel

Quick links to important sections

Medijel

Treatment option: Canker Sore, Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medijel

What is Medijel and What Type of Medicine is It?

Medijel is a specialized Oral Gel classified as a Combination Local Anesthetic and Antiseptic product, intended for targeted application to the mucous membranes of the mouth (topical/oromucosal route of administration). The preparation is a synthetic medicine, designed to adhere effectively to the moist buccal tissues, ensuring focused and sustained action at the site of discomfort. Its active components are formulated for localized symptomatic management, providing temporary numbing of the oral mucosa.

Composition: The Dual-Active Synergy of Lidocaine and Aminoacridine

The product's efficacy is driven by the strategic combination of two active ingredients: Lidocaine Hydrochloride and Aminoacridine Hydrochloride, formulated within an aqueous viscous gel base. Lidocaine Hydrochloride belongs to the amide-type local anesthetic class, which functions by temporarily blocking nerve signals to achieve numbing. Aminoacridine Hydrochloride, an acridine derivative, is incorporated as an antiseptic to provide localized germicidal action. This specific formulation establishes Medijel as a dual-active treatment, combining localized pain management with surface hygiene maintenance.

General Purpose: Localized Numbing and Germ Protection

The overarching therapeutic purpose of Medijel is to deliver fast-acting relief from localized oral discomfort through its dual functionality, targeting minor irritations such as sore gums or simple tissue abrasions. The local anesthesia provided by the Lidocaine component achieves localized pain relief by interrupting pain signals precisely at the affected site. Concurrently, the Aminoacridine component contributes to surface germicidal action, inhibiting the growth of microorganisms. This action is intended to provide immediate relief while supporting the maintenance of the oral environment during the natural healing process.

Regulatory References

  1. MedlinePlus

What side effects are possible with Medijel?

Possible side effects and safety information

The safety profile of Medijel is officially documented in government regulatory sources, focusing on adverse reactions and specific usage constraints. The most frequent reactions observed are generally localized administration site conditions, which may include a transient sensation of irritation or stinging upon application to the oral mucosa.

Adverse effects are categorized by System-Organ Class. Immune System Disorders are documented as a potential concern, encompassing hypersensitivity reactions to the active ingredients. Such allergic events, while reported on rare occasions, can manifest as more severe reactions like angioedema or severe systemic hypersensitivity. The product label also notes the potential for contact dermatitis.

Serious Adverse Reactions and Population Constraints

Serious adverse reactions, most often associated with misuse, include symptoms of Systemic Toxicity following excessive use or accidental ingestion. These documented effects may involve the central nervous system or cardiovascular system, presenting as dizziness, hypotension, or, in severe cases, convulsions and cardiac standstill. The potential for suppression of pharyngeal sensation is also noted with excessive topical application.

Regulatory safety constraints explicitly restrict use of the medicine. It is not suitable for children under 6 years of age and is specifically contraindicated for the treatment of teething in children, based on official safety reviews of oral lidocaine-containing products. Furthermore, the gel is contraindicated in individuals with known hypersensitivity to Lidocaine, Aminoacridine, or other amide-type local anesthetics, or those with specific rare hereditary sugar intolerances.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this preparation is primarily associated with the risk of systemic absorption of the local anesthetic component, Lidocaine Hydrochloride, which can lead to Systemic Toxicity.

Documented Manifestations and Severe Outcomes

Initial symptoms documented in regulatory information include Central Nervous System (CNS) effects such as tinnitus, lightheadedness, and metallic taste, progressing to confusion, muscle twitching, and eventually convulsions (seizures) or loss of consciousness. Severe systemic toxicity poses a risk of Cardiovascular Collapse (hypotension, bradycardia) and Respiratory Arrest. A specific documented outcome is Methemoglobinemia.

Regulator-Mandated Emergency Actions

The onset of any signs of systemic toxicity strictly mandates the individual to seek immediate medical attention or contact emergency services. Specific documented management procedures involve ensuring a patent airway and providing assisted ventilation. Pharmacological measures, such as the use of Intravenous Lipid Emulsion and other supportive agents, are documented for managing severe cardiovascular and respiratory compromise.

Population-Specific Notes

Increased risk of toxicity is officially noted for debilitated or elderly patients and those with severe hepatic disease. Infants under six months of age are particularly susceptible to the complication of Methemoglobinemia.

Therapeutic Uses of Medijel

What Medijel treats: Main Uses and Benefits

Medijel is primarily used for targeted, short-term symptomatic assistance across specific domains of oral discomfort in patients aged six years and older. The medication is used for symptomatic assistance with several common oral irritations.

It is commonly used across conditions presenting with acute episodes of localized pain, including common mouth ulcers, soreness and irritation caused by denture rubbing, and other minor tissue abrasions. A key therapeutic benefit is symptomatic relief that assists patients to cope more steadily with difficult, localized pain. Furthermore, the inclusion of an antiseptic provides a localized germicidal action, which may assist with managing symptomatic manifestations related to surface contamination.

Therapeutic Benefit

When symptoms intensify and create noticeable interference with functions like eating or speaking, the medication provides support that helps ease the overall symptom burden. It addresses symptom clusters related to physical discomfort and inflammatory or irritative states.

Key Use: Symptom Management for Oral Discomfort
It is considered relevant in contexts where temporary assistance in symptom stabilization is needed for short-term oral pain.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Medijel

Medijel is subject to specific regulatory eligibility rules that define who can and cannot use the oral gel, based on age, known allergies, and certain pre-existing conditions. All eligibility information is strictly derived from official government-approved labeling.


Populations Contraindicated (Must Not Use)

Classification Rule
Hypersensitivity Contraindicated in individuals with known allergy (hypersensitivity) to the active substances (Lidocaine Hydrochloride or Aminoacridine Hydrochloride) or any other component (excipient) in the formulation.
Metabolic Conditions Contraindicated in patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency due to an excipient (sucrose) in the gel.

Age-Related Eligibility and Restrictions

Age Group Eligibility Status
Adults & Adolescents Permitted for use in adults and adolescents aged 12 years and over.
Children Not suitable for children under 6 years of age. Use is permitted only for children aged 6 years and over.

Conditional and Restricted Use

Medijel is not suitable for the treatment of teething in children. Regarding pregnancy and lactation, the official labeling indicates that while safety has not been established, the medicine is considered not to constitute a hazard during these periods. No specific restrictions or contraindications related to hepatic or renal impairment are documented in the labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for Medijel, based on the active ingredient Lidocaine Hydrochloride, outlines specific patterns of interaction that are classified as either pharmacokinetic or pharmacodynamic in nature.

Pharmacokinetic and Metabolic Interactions

Co-administration with potent inhibitors of the CYP3A4 and CYP1A2 enzymes is documented to present a pharmacokinetic interaction risk. This regulatory classification is based on the potential for these substances to reduce the clearance of the active ingredient, resulting in increased systemic exposure (AUC and Cmax). Furthermore, medicines documented to decrease hepatic blood flow may also contribute to reduced clearance, thereby increasing exposure to the active substance.

Pharmacodynamic Interactions

The official profile notes a pharmacodynamic interaction risk with certain co-administered medicinal products. This is specifically relevant for other local anesthetics and Class I antiarrhythmic drugs, where co-administration is officially described as carrying a risk of additive effects on the central nervous and cardiovascular systems.

Restrictions and Population-Specific Notes

Interaction-Context Constraint Regulatory Statement
Timing Requirements No mandatory dose separation or timing rules are specified for this topical formulation.
Food/Alcohol No specific interactions with food, alcohol, or common herbal products are documented in the label.
Population Note The interaction risk may be intensified in individuals with hepatic impairment due to reduced drug clearance.

Mechanism of Action

Medijel contains lidocaine and cetalkonium chloride. The primary mechanism is mediated by lidocaine, which acts as a voltage-gated sodium channel inhibitor. Upon topical application, the lipophilic, uncharged form of lidocaine permeates neuronal cell membranes in the targeted oral tissue. Intracellularly, it becomes protonated to its charged, active form, which then accesses and binds to the inner pore of the neuronal Nav channels (primarily Nav1.7, Nav1.8, and Nav1.9 isoforms). This binding is state-dependent, exhibiting higher affinity for the open and inactivated conformations of the channel. The charged molecule physically blocks the channel pore, preventing the influx of Na^+ ions. This inhibition raises the threshold for electrical excitability, impeding the rapid depolarization required for action potential generation and propagation along the sensory nerve fibers. The downstream cascade is a systemic blockade of afferent neural signal transmission from the application site, resulting in localized modulation of physiological sensation. Concurrently, cetalkonium chloride, a cationic surfactant, interacts with negatively charged components of microbial cell membranes, disrupting the membrane's integrity. This quaternary ammonium compound causes leakage of intracellular contents, leading to cellular destabilization and, in high local concentrations, inactivation of key microbial enzymes and denaturation of proteins.

Dosage and Administration Information

Medijel is an oromucosal gel containing the local anesthetic Lidocaine hydrochloride and the antiseptic Aminoacridine hydrochloride. It is indicated for the temporary relief of pain associated with common mouth ulcers, sore gums, and denture rubbing.

Administration Instructions

Follow these guidelines for the correct application of Medijel Gel:

  1. Preparation: Wash and thoroughly dry your hands before use.
  2. Application: Apply a small quantity of gel onto a clean fingertip or a small cotton-wool pad.
  3. Treatment: Gently massage the gel directly onto the painful, affected area(s) inside the mouth.

Dosage and Frequency

Age Group Maximum Frequency of Application
Adults and Children (6 years and over) Repeat the application every 20 minutes if necessary, or less frequently (e.g., every 3 hours) as symptoms require.
Children under 6 years Not suitable for use.

Note: If symptoms of pain, irritation, or soreness persist for more than seven days after using this product, consult a doctor or dentist for further evaluation.

Safety Considerations

Medijel Gel is for oromucosal application only and should not be swallowed. Do not use this product if you have a known hypersensitivity or allergy to Lidocaine or any of the inactive ingredients listed in the product formulation. The gel contains small amounts of ethanol and sucrose; patients with rare hereditary sugar intolerances should consult a healthcare professional before use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Medijel

This overview provides a description of the research structures and available evidence for Medijel (Lidocaine Hydrochloride 0.66% w/w / Aminoacridine Hydrochloride 0.05% w/w oral gel), focusing on what studies have explored and where the limitations exist. This information is intended to contextualize the product's authorization and does not contain clinical advice, dosing instructions, or safety information.


Evidence for Use in Common Mouth Ulcers

Research examining Medijel for common mouth ulcers was studied for temporary symptomatic assistance in conditions associated with acute or disruptive episodes. The research base primarily relies on the established pharmacological activity of the two main components: Lidocaine, a substance observed in studies for its anesthetic properties in the application area; and Aminoacridine, a component studied for its surface hygiene properties. Available data structures have involved observations from post-marketing surveillance and safety reports, rather than extensive, product-specific randomized controlled trials comparing the dual-active gel to a placebo. Studies focused on outcomes related to physical discomfort, often measuring patient-reported outcomes describing perceived discomfort and the assessment of symptom stabilization. Studies report patterns related to the temporary loss of sensation measured after application of the anesthetic component.

Evidence for Use in Soreness Caused by Denture Rubbing

The research base related to using the gel for acute soreness and irritation due to denture rubbing is derived from established data regarding topical anesthetics. The evidence was observed in contexts where topical local anesthetics are commonly used for mechanical discomfort. The available data structures for this use explored primarily patient-reported outcomes describing perceived discomfort and localized pain measures experienced by adult denture wearers. The research provides insight into short-term changes in outcomes related to physical discomfort during acute episodes. Findings describe patterns observed in the studies focused on outcomes related to physical discomfort during acute episodes. However, comparative evidence is lacking for the specific dual-active gel against other single-active treatments used for denture irritation.


What Remains Unclear or Under-Studied

A key limitation of the evidence base is the lack of publicly cited, product-specific randomized controlled trials (RCTs) that directly compare the dual-active gel to a placebo or alternative treatments for all approved indications. The evidence was evaluated in the context of the long-standing authorization and established mechanism of action of the components. The evidence quality varies across studies, and the results apply only to the populations studied, meaning the research does not determine whether an individual will respond similarly. Long-term effects are not fully established by the existing research base, as follow-up durations were typically limited to the acute use period.

Key Studies & References Lidocaine/Aminoacridine Oral Gel Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Medijel (FAQ)


Q: How quickly should I feel Medijel working after I apply it?

Medijel contains Lidocaine, a local anesthetic. Official information indicates that the pain relief effect is prompt, commonly observed within a few minutes of application to the affected area. This is due to the fast-acting nature of the anesthetic component on mucous membranes.

Q: How long does the pain relief from Medijel typically last?

The effect is characterized as temporary and short-acting. The product leaflet permits repeating the application every 20 minutes if necessary, or less frequently as symptoms require. Consult the dosage instructions for the maximum frequency of use.

Q: Why do some people say Medijel feels like it burns for a second?

Official safety data documents that a transient sensation of localized irritation or stinging upon application is among the most frequent reactions observed. This transient sensation is generally observed to be short-lived, resolving as the anesthetic effect takes hold.

Q: Is it normal to feel a slight stinging or numbness right after applying Medijel?

Yes, a transient stinging or irritation is documented as a frequent localized reaction. Numbness is the expected result of the local anesthetic action of Lidocaine, as it temporarily blocks pain signals in the application area.

Q: Does Medijel actually help the mouth ulcer heal, or just numb the pain?

Medijel is officially indicated for the temporary relief of pain (numbing) from mouth ulcers. It contains the antiseptic Aminoacridine, which provides surface germicidal action, helping to maintain oral hygiene at the site of the sore.

Q: How long can I keep using Medijel for a persistent mouth sore?

Medijel is indicated for temporary relief. Official guidance advises consulting a doctor or dentist for further evaluation if symptoms of pain, irritation, or soreness persist for more than seven days following the use of the product.

Q: Can Medijel interact with herbal supplements like St. John's Wort?

Official product information states no specific interactions with common herbal products are documented on the label for this topical formulation. No mandatory separation or timing rules are specified for use alongside herbal supplements.

Q: Is Medijel the same as Bonjela or is there a difference?

Medijel contains the active ingredients Lidocaine and Aminoacridine. Other popular oral gels, such as Bonjela Adult, typically contain different active substances, like choline salicylate and cetalkonium chloride, resulting in different formulations.

Q: What happens if I accidentally swallow a little bit of Medijel?

Medijel is for oromucosal application only and is not intended to be swallowed. However, official regulatory sources state that the risk of toxic effects from accidental ingestion of a small amount is considered low due to the low concentration of active ingredients.

Q: Are there any common foods or drinks I should avoid while using Medijel?

The official product label does not document any specific interactions with food or alcohol. However, it is noted that excessive topical use may cause temporary suppression of pharyngeal (throat) sensation, which could potentially affect swallowing.

Q: Is Medijel safe to use if I have dentures or braces?

Medijel is officially indicated for temporary pain relief associated with denture rubbing and sore gums. No specific contraindications are listed in the product information regarding use with braces or other dental appliances.

Q: Can using Medijel too often cause any long-term issues in the mouth?

Long-term effects are not fully established as the product is intended for acute, short-term use. Prolonged or excessive application carries the potential for systemic effects, and misuse should be avoided.

Q: Are there different versions or strengths of Medijel available?

According to official documentation, Medijel is authorized as a single formulation: an oral gel containing Lidocaine Hydrochloride 0.66% w/w and Aminoacridine Hydrochloride 0.05% w/w.

Q: Why is there a limit on how long I can use Medijel continuously?

Regulatory guidance advises seeking evaluation from a healthcare professional if symptoms persist after seven days of use. This measure ensures that persistent pain is evaluated for any underlying condition that may require a different treatment approach.

Q: What research supports the use of Medijel for general sore mouth?

Research supporting Medijel focuses on temporary symptomatic assistance for conditions associated with acute or disruptive episodes, specifically mouth ulcers and irritation from denture rubbing. The evidence is based on the known pharmacological actions of its components.

Q: Can Medijel be used by people who have had gastric bypass surgery?

Medijel contains sucrose. Official contraindications state that the product is not suitable for patients with rare hereditary problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.

Q: Are there any medications that Medijel is known to interfere with badly?

Official information states that due to the active ingredient Lidocaine, co-administration with other local anesthetics or Class I antiarrhythmic drugs carries a risk of additive effects on the central nervous and cardiovascular systems.

Q: Can I apply Medijel on a dry cotton swab instead of my finger?

The official administration instructions state that the gel should be applied directly to the affected area using either a clean fingertip or a small pad of cotton wool.

Q: Are there studies that show how effective Medijel is for gum irritation?

Studies examining Medijel focus on common mouth ulcers and soreness caused by denture rubbing. Product-specific studies are not documented for its use in general gum irritation beyond these core indications.

Q: Does Medijel contain alcohol or any other drying agents?

Yes, Medijel contains small amounts of ethanol (alcohol) in its formulation. Other excipients include sucrose, a sugar, and various thickening agents.

Q: Are there specific studies on Medijel's use in pregnant women, just for general knowledge?

The safety of Medijel during pregnancy and lactation has not been formally established through specific trials. However, based on official safety reviews, the medicine is considered not to pose a significant risk during these periods.

Q: Does Medijel come in different flavors?

The official product formulation includes Peppermint Oil and Ethyl Vanillin as inactive ingredients (excipients), which contribute to the flavor profile of the gel.

Q: Is Medijel effective for pain caused by ill-fitting retainers?

Medijel is indicated for the temporary relief of pain associated with localized mechanical irritation, such as denture rubbing. Its indication is relevant to the type of irritation that may be caused by ill-fitting retainers or other dental appliances.

Q: Are there any visible signs that indicate I should stop using Medijel immediately?

Any signs of a severe hypersensitivity reaction to the active ingredients, such as a widespread rash, swelling of the face or mouth (angioedema), or difficulty breathing, are listed in official safety documents as reasons to seek immediate medical advice.

Q: Does the efficacy of Medijel decrease over time if the tube is old?

Medijel has an approved shelf life of 36 months when stored under specified conditions. To ensure full effectiveness, the product must not be used after the expiry date indicated on the packaging.

Q: Is the quantity of the active ingredient in Medijel considered low-risk?

Official safety information notes that due to the low concentration of Lidocaine, it is considered unlikely that toxic effects would be reached with appropriate topical use, even if used at the maximum frequency.

Q: Does Medijel contain sugar or artificial sweeteners?

Yes, the product formulation contains both sucrose (a type of sugar) and Saccharin Sodium (an artificial sweetener) as excipients.

How should Medijel be stored and disposed of?

Official Storage Requirements

Medijel is subject to specific regulatory requirements intended to maintain product stability and integrity throughout its shelf life. Official labeling mandates that the product must not be stored above 25 C. The medicine must be kept in its original packaging, which is specified as an aluminium tube with a membrane seal and spiked polyethylene cap, to ensure the container's integrity.

Stability and Disposal

The approved shelf life for the product when stored under the specified conditions is 36 months. When the medicine is expired or no longer needed, official disposal instructions advise returning the unused quantity to a pharmacist or destroying it in accordance with local regulations for medicinal waste. These rules govern the proper management of the medicine from packaging until its destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Medijel found in:

A-Z Index: